Literature DB >> 33671257

Unique Cytokine Response in West Nile Virus Patients Who Developed Chronic Kidney Disease: A Prospective Cohort Study.

Michael Hansen1, Melissa S Nolan2, Rodion Gorchakov3, Rodrigo Hasbun4, Kristy O Murray3, Shannon E Ronca3.   

Abstract

West Nile virus (WNV) is a widespread and devastating disease, especially in those who develop neuroinvasive disease. A growing body of evidence describes sequelae years after infection, including neurological complications and chronic kidney disease (CKD). Eighty-nine out of 373 WNV-positive cases were followed for approximately two years and compared to 127 WNV-negative controls with and without CKD. Adjusted risk ratios (aRRs) were calculated via a log binomial regression to determine the impact of WNV exposure and other possible confounders on the likelihood of developing CKD. Cytokine profiles of WNV patients and controls were evaluated to characterize differences and describe potential underlying pathophysiological mechanisms. The associated risk for developing CKD was significantly associated with history of WNV infection (aRR = 1.91, 95% CI 1.13-3.25). Additionally, five distinct cytokines were found to be significantly associated with WNV infection (eotaxin, IL-8, IL-12p70, IP-10, and TNFα) after the p-value was adjusted to <0.0019 due to the Bonferroni correction. These data support that WNV infection is an independent risk factor for CKD, even after accounting for confounding comorbidities. WNV participants who developed CKD had high activity of proinflammatory markers, indicating underlying inflammatory disease. This study provides new insights into CKD resultant of WNV infection.

Entities:  

Keywords:  Flavivirus; West Nile virus; chemokine; chronic kidney disease; cytokine; proinflammatory

Mesh:

Substances:

Year:  2021        PMID: 33671257      PMCID: PMC7922428          DOI: 10.3390/v13020311

Source DB:  PubMed          Journal:  Viruses        ISSN: 1999-4915            Impact factor:   5.048


  42 in total

1.  West Nile virus-specific CD4 T cells exhibit direct antiviral cytokine secretion and cytotoxicity and are sufficient for antiviral protection.

Authors:  James D Brien; Jennifer L Uhrlaub; Janko Nikolich-Zugich
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

2.  Study on West Nile virus persistence in monkeys.

Authors:  V V Pogodina; M P Frolova; G V Malenko; G I Fokina; G V Koreshkova; L L Kiseleva; N G Bochkova; N M Ralph
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

Review 3.  Innate immune control of West Nile virus infection.

Authors:  Alvaro Arjona; Penghua Wang; Ruth R Montgomery; Erol Fikrig
Journal:  Cell Microbiol       Date:  2011-09-22       Impact factor: 3.715

4.  IP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIV.

Authors:  Karolin Falconer; Galia Askarieh; Nina Weis; Kristoffer Hellstrand; Annette Alaeus; Martin Lagging
Journal:  Scand J Infect Dis       Date:  2010-07-07

Review 5.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

6.  Initial and long-term costs of patients hospitalized with West Nile virus disease.

Authors:  J Erin Staples; Manjunath B Shankar; James J Sejvar; Martin I Meltzer; Marc Fischer
Journal:  Am J Trop Med Hyg       Date:  2014-02-10       Impact factor: 2.345

Review 7.  West Nile virus: immunity and pathogenesis.

Authors:  Stephanie M Lim; Penelope Koraka; Albert D M E Osterhaus; Byron E E Martina
Journal:  Viruses       Date:  2011-06-15       Impact factor: 5.048

8.  Use of Testing for West Nile Virus and Other Arboviruses.

Authors:  Jakapat Vanichanan; Lucrecia Salazar; Susan H Wootton; Elizabeth Aguilera; Melissa N Garcia; Kristy O Murray; Rodrigo Hasbun
Journal:  Emerg Infect Dis       Date:  2016-09       Impact factor: 6.883

9.  Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.

Authors:  Florian Douam; Yentli E Soto Albrecht; Gabriela Hrebikova; Evita Sadimin; Christian Davidson; Sergei V Kotenko; Alexander Ploss
Journal:  mBio       Date:  2017-08-15       Impact factor: 7.867

10.  Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase.

Authors:  Dennis Tappe; José Vicente Pérez-Girón; Lorenzo Zammarchi; Jürgen Rissland; Davis F Ferreira; Thomas Jaenisch; Sergio Gómez-Medina; Stephan Günther; Alessandro Bartoloni; César Muñoz-Fontela; Jonas Schmidt-Chanasit
Journal:  Med Microbiol Immunol       Date:  2015-12-24       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.